Should I Buy ORGO? ORGO 2026 Analysis

Should You Buy Organogenesis Holdings Inc (ORGO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.010

1 Day change

3.08%

52 Week Range

7.080

Analysis Updated At

2026/01/30

ORGO is not a good buy right now for an impatient buyer. Despite solid Q3 growth and supportive (bullish-leaning) options positioning, the primary trend is still bearish (SMA_200 > SMA_20 > SMA_5), the stock is sitting just below near-term resistance (~4.06), insider selling has spiked sharply, and the pattern-based outlook points to downside over the next week/month. I would avoid initiating a new position at the current 4.01 pre-market level.

Technical Analysis

Price/Trend: The moving-average stack is bearish (SMA_200 > SMA_20 > SMA_5), signaling the dominant trend remains down despite a short-term stabilization attempt. Momentum: MACD histogram is positive and expanding (0.022), indicating improving short-term momentum, but RSI(6) ~50.4 is neutral—no strong thrust signal. Levels: Pivot 3.867 is the key line to hold. Immediate resistance is R1 ~4.06 (price 4.01 is already close), then R2 ~4.179. Supports are S1 ~3.674 and S2 ~3.555. From an impatient-entry perspective, buying right under resistance with a bearish MA structure is unattractive. Pattern/Forward bias: Similar-pattern stats suggest ~+0.52% next day but -5.9% next week and -6.12% next month, which argues against buying now. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios below 1 (OI PCR 0.65; Volume PCR 0.61) lean bullish, suggesting more call positioning than puts. Activity: Today’s option volume is elevated vs 30-day average (22.03x), and today’s open interest is also elevated vs average (235.92x), which can indicate heightened attention/positioning. Volatility: IV (30D) ~89.9 vs historical vol ~123 suggests IV is not extremely stretched; IV percentile ~24.8 and IV rank ~14.9 are relatively low, implying options are not priced at peak fear levels. Net: options positioning is constructive, but it is not strong enough to override the bearish technical backdrop and insider selling.

Technical Summary

Sell

Buy

Positive Catalysts

Fundamentals: 2025/Q3 showed strong growth (revenue +30.98% YoY; EPS +22.22% YoY), supporting a medium-term bull case.
Industry/reimbursement positioning: BTIG sees Organogenesis as potentially a share winner under 2026 reimbursement dynamics due to its pricing structure.
Options sentiment: Put/call ratios (OI and volume) are bullish-leaning, indicating traders are positioned for upside or protection is relatively light.

Neutral/Negative Catalysts

Trend/price action: Bearish moving-average structure and price sitting just below resistance (~4.
makes the immediate setup poor for an impatient entry.
Insider selling: Insiders are selling, with selling amount up ~1870% over the last month—often a meaningful near-term confidence/supply overhang signal.
Reimbursement uncertainty timing: BTIG reduced confidence in ORGO as a 2026 Top Pick after CMS indicated it would not implement final Skin-Sub LCDs on Jan 1, 2026; this kind of policy timing uncertainty can cap near-term multiple expansion.
No fresh news catalyst: No news in the last week to drive an immediate breakout.
Model/pattern bias: Statistical projection points to weakness over 1-week and 1-month horizons.

Financial Performance

Latest quarter: 2025/Q3. Revenue rose to $150.864M (+30.98% YoY). Net income increased to $14.525M (+17.79% YoY). EPS was $0.11 (+22.22% YoY). Gross margin dipped to 75.97% (-0.99% YoY). Overall: strong top-line and earnings growth, with a modest margin headwind—fundamentals are improving, but the stock setup/flows are currently the bigger constraint for a ‘buy now’ decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: BTIG has maintained a Buy rating and lifted its price target to $9 from $7 (2025-11-20), then later reiterated Buy and $9 (2025-12-26) but explicitly reduced confidence in naming it a 2026 Top Pick due to the CMS LCD implementation delay. Wall Street pro view (pros): Potential share winner in 2026 reimbursement framework; attractive relative positioning as a lower-cost provider; PT implies large upside vs ~$4. Wall Street con view (cons): Policy/reimbursement timing uncertainty can delay the thesis; near-term visibility and sentiment can be disrupted by CMS updates. Influential buyers/sellers: No recent congress trading data available; hedge funds noted as neutral; insiders are net sellers and selling has accelerated materially.

1 Analyst Rating

Wall Street analysts forecast ORGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORGO is 9 USD with a low forecast of 9 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.890

Low

Averages

High

Current: 3.890

Low

Averages

High

BTIG

Buy

maintain

AI Analysis

2025-12-26

Reason

BTIG

Price Target

AI Analysis

2025-12-26

maintain

Buy

Reason

BTIG keeps a Buy rating and $9 price target on Organogenesis but notes that the firm's confidence on the stock as 2026 Top Pick is being reduced. BTIG cites CMS announcing that it would not implement the final Skin-Sub LCDs - Local Coverage Determinations - on January 1, 2026, noting that this unexpected update comes just 9 days after CMS announced that the MACs would be implementing the LCDs but with products classified into 3 categories - covered, non-covered, and 12-month status quo - even though the firm still believes that low-cost providers such as Organogenesis will be best-positioned in the market, the analyst tells investors in a research note.

BTIG

Buy

maintain

$7 -> $9

2025-11-20

Reason

BTIG

Price Target

$7 -> $9

2025-11-20

maintain

Buy

Reason

BTIG raised the firm's price target on Organogenesis to $9 from $7 and keeps a Buy rating on the shares. With the changes in reimbursement set to take effect in 2026, there will be clear share winners and share losers, and the firm believes that Organogenesis will be one of those that may be a share winner based on its current product pricing structure relative to the finalized pricing structure at $127.28 per cm, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ORGO

Unlock Now

ORGO Should I Buy

ORGO Should I Buy

Should You Buy Organogenesis Holdings Inc (ORGO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch